fbpx

clinical trial

PEACE trial opens to recruitment

ANZGOG’s new study for patients with advanced gynaecological cancer, PEACE, has officially opened to recruitment after activating its first site, Canberra Hospital. Led by Principal Investigator Dr Alison Davis in Australia, the international study [...]

PEACE trial opens to recruitment2023-10-18T12:01:14+11:00

Mother and daughter educating the doctors of tomorrow about gynaecological cancer

Jenny and her daughter Kathryn are both advocates for ANZGOG’s Survivors Teaching Students (STS) program in QLD, Australia and New Zealand respectively. “One of the first things I wanted to do when diagnosed was [...]

Mother and daughter educating the doctors of tomorrow about gynaecological cancer2023-10-18T12:03:47+11:00

Dr Jeffrey Goh explains ITTACc – ANZGOG’s latest cervical cancer study

ITTACc is ANZGOG’s phase II, randomised multi-centre non-comparative trial of sitravatinib in recurrent or metastatic cervical cancer that have progressed after standard therapies. ANZGOG spoke with ITTACc Principal Investigator, Dr Jeffrey Goh, who explained the study [...]

Dr Jeffrey Goh explains ITTACc – ANZGOG’s latest cervical cancer study2023-10-18T12:05:35+11:00

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment

EMBRACE is a Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2. Dr Katrin Sjoquist, Medical Oncologist [...]

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment2022-07-01T11:34:46+10:00
Go to Top